|Bid||1,800.00 x 346500|
|Ask||1,805.00 x 57900|
|Day's Range||1,775.00 - 1,808.00|
|52 Week Range||1,505.00 - 2,320.00|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||7,520.83|
|Earnings Date||Feb 1, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Rehovot, Israel-based company said it had a loss of 6 cents per share. Losses, adjusted for stock option expense, came to 5 cents per share. The biopharmaceutical posted revenue of $15 million in the ...
REHOVOT, Israel, Nov. 05, 2018 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Eitan Kyiet as Vice President of Business Development. Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry. Mr. Kyiet will report directly to Amir London, Kamada’s Chief Executive Officer.
REHOVOT, Israel, Sept. 25, 2018-- Kamada Ltd., a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor ...
The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rehovot, Israel-based company said it had profit of 14 cents. The biopharmaceutical posted revenue of $33.8 million in the period. Kamada shares have climbed 22 percent since ...
On a per-share basis, the Ness Ziona, Israel-based company said it had profit of 3 cents. The biopharmaceutical posted revenue of $17.4 million in the period. Kamada expects full-year revenue in the range ...
Kedrion Biopharma and Kamada Ltd. (KMDA) (KMDA.TA), two leading human-derived protein therapeutics companies, announced today that KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches. KEDRAB, a human rabies immune globulin (HRIG), received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two HRIG therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus. KEDRAB, the newest entry into the $100 million plus U.S. rabies market, represents another safe, effective treatment choice for healthcare professionals seeking an alternative to currently available HRIGs.
On a per-share basis, the Ness Ziona, Israel-based company said it had net income of 16 cents. The biopharmaceutical posted revenue of $35.7 million in the period. For the year, the company reported net ...